drugset / Trial / NCT00065533

Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer

NCT00065533 ↗

Phase 2 Completed 92 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study are to determine the safety of pemetrexed and any side effects that might be associated with it, whether pemetrexed can help patients with breast cancer and how much pemetrexed should be given to patients.

Timeline

Start
2003-05
Primary completion
—
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule — —

Indications